Bioinformatics analysis of TP53 expression in hepatocellular carcinoma and its effect on clinical prognosis

doi:10.3877/cma.j.issn.2095-3232.2022.01.018

Abstract

Abstract:

Objective

To investigate the expression level of TP53 in hepatocellular carcinoma (HCC) by online database and assess its effect on the clinical prognosis.

Methods

The expression level of TP53 in common tumors was analyzed by using Sangerbox Tools platform. The relationship between TP53 expression and clinical characteristics of HCC patients was analyzed by UALCAN database. The relationship between TP53 expression and clinical prognosis of HCC patients was assessed by Kaplan-Meier Plotter database. The effect of TP53 gene mutation and expression changes on the survival and prognosis of HCC patients was evaluated by CBioPortal database. Survival analysis was performed by Kaplan-Meier method and Log-rank test.

Results

Sangerbox Tools platform analysis demonstrated that the expression level of TP53 in HCC was significantly higher than that in normal liver tissues (P<0.001). UALCAN and CBioPortal databases showed that the expression levels of TP53 significantly differed between AJCC stage Ⅰ and Ⅲ, histological grade 1 and 3, grade 2 and 3 HCC (P=0.024, <0.001, 0.012). The expression level of TP53 was correlated with gender, which was significantly up-regulated in female HCC patients (P=0.013). CBioPortal database analysis revealed that the mutation rate of TP53 was associated with the histological grade of HCC. The higher the mutation rate, the higher the histological grade (P<0.001). UALCAN database showed that the overall survival of HCC patients with low expression of TP53 was better (P=0.019). CBioPortal analysis demonstrated that the overall survival, disease-specific survival, progression-free survival and disease-free survival of HCC patients without TP53 gene mutation were significantly better compared with those of their counterparts with TP53 gene mutation (HR=8.002, 6.592, 5.591, 5.618; P<0.05).

Conclusions

Online analysis platform indicates that TP53 is highly expressed in HCC. The expression level of TP53 is correlated with the clinical characteristics and prognosis of HCC patients. Patients with low expression of TP53 and those without TP53 gene mutation can obtain favorable clinical prognosis.

Key words: Genes, p53, Carcinoma, hepatocellular, Prognosis, Computational biology

Zhou Yang, Linsen Ye, Xiao Feng, Yunliang Xie, Xiaobin Li, Binsheng Fu. Bioinformatics analysis of TP53 expression in hepatocellular carcinoma and its effect on clinical prognosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(01): 87-91.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2022.01.018

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2022/V11/I01/87

Figures/Tables 3

References 21

[1]	Sung H, Ferlay J, Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2]	Anzola M, Burgos JJ.Hepatocellular carcinoma: molecular interactions between hepatitis C virus and p53 in hepatocarcinogenesis[J].Expert Rev Mol Med,2003,5(28):1-16.
[3]	Qi LN, Bai T, Chen ZS,et al.The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China: role of chronic hepatitis B virus infection and aflatoxin B1 exposure[J].Liver Int,2015,35(3):999-1009.
[4]	Olivier M, Hussain SP, Caron de Fromentel C,et al.TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer[J].IARC Sci Publ,2004(157):247-270.
[5]	Chandrashekar DS, Bashel B, Balasubramanya SAH,et al.UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J].Neoplasia,2017,19(8):649-658.
[6]	Menyhárt O, Nagy Á, Győrffy B.Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma[J].R Soc Open Sci,2018,5(12):181006.
[7]	Cerami E, Gao J, Dogrusoz U,et al.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J].Cancer Discov,2012,2(5):401-404.
[8]	Gao J, Aksoy BA, Dogrusoz U,et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J].Sci Signal,2013,6(269):pl1.
[9]	Cao W, Chen HD, Yu YW,et al.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chin Med J (Engl)，2021,134(7):783-791.
[10]	Arnold M, Abnet CC, Neale RE,et al.Global burden of 5 major types of gastrointestinal cancer[J].Gastroenterology,2020,159(1):335-349，e15.
[11]	Marcel V, Perrier S, Aoubala M,et al.Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript[J].FEBS Lett,2010,584(21):4463-4468.
[12]	Yin Y, Stephen CW, Luciani MG,et al.p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products[J].Nat Cell Biol,2002,4(6):462-467.
[13]	Szymańska K, Hainaut P.TP53 and mutations in human cancer[J].Acta Biochim Pol,2003,50(1):231-238.
[14]	Zhao L, Qu X, Wu Z,et al.TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy[J].Aging,2020,12(14):14556-14568.
[15]	Yoshii S, Hayashi Y, Iijima H,et al.Exosomal microRNAs derived from colon cancer cells promote tumor progression by suppressing fibroblast TP53 expression[J].Cancer Sci,2019,110(8):2396-2407.
[16]	Aukema SM, Hoster E, Rosenwald A,et al.Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network[J].Blood,2018,131(4):417-420.
[17]	Pandya JA, Boaz K, Natarajan S,et al.A correlation of immunohistochemical expression of TP53 and CDKN1A in oral epithelial dysplasia and oral squamous cell carcinoma[J].J Cancer Res Ther,2018,14(3):666-670.
[18]	Kurdi M, Butt NS, Baeesa S,et al.Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies[J].J Neurooncol,2021,152(3):541-549.
[19]	Li LK, Kong ZH.Screening and functional analysis of micro-RNAs that regulate the expression of the tumor suppression TP53 gene[J].Eur Rev Med Pharmacol Sci,2018,22(7):1937-1942.
[20]	Simons RL, Lei MK, Carter S,et al.Inflammation mediates the effect of discrimination, religiosity, and friendship network on expression of the Tp53 cancer suppressor gene[J].SSM Popul Health,2019(7):100389.
[21]	Williams DS, Mouradov D, Browne C,et al.Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stageⅢ colorectal cancer[J].Mod Pathol,2020,33(3):483-495.

Please choose a citation manager

Content to export